GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

Phase 1/2 Unknown 36 enrolled AO GENERIUM

Non-randomizedSequentialOpen-labelTreatment

It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-084.

Evaluation	Drug	Modality	Dose	Route
Subject	GNR-084	Unknown	0.01 ng	Intravenous
Subject	GNR-084	Unknown	0.1 ng	Intravenous
Subject	GNR-084	Unknown	1 ng	Intravenous
Subject	GNR-084	Unknown	4 ng	Intravenous
Subject	GNR-084	Unknown	10 ng	Intravenous
Subject	GNR-084	Unknown	20 ng	Intravenous